Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10614388 | 0.90 | ADORA2B (0.60) | ADORA2BADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL10614407 | 0.89 | ADORA2B (0.71) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL10614242 | 0.84 | ADORA2B (0.53) | ADORA2BADORA2A | |
| SCHEMBL10614202 | 0.84 | ADORA2B (0.70) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL10614067 | 0.83 | ADORA2B (0.60) | ADORA2BADORA2AADORA1 | |
| SCHEMBL10614219 | 0.83 | ADORA2B (0.52) | ADORA2BADORA2AADORA1 | |
| SCHEMBL10856890 | 0.82 | ADORA2B (0.61) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL10614807 | 0.81 | ADORA2B (0.57) | ADORA2BKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10616203 | 0.81 | ADORA2B (0.51) | ADORA2BADORA2A | |
| SCHEMBL10616213 | 0.81 | PDE5A (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | claimed |
| EP-3876871-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | The Regents of the University of California (US) | 2021-09-15 | — | — | EP | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| EP-0970696-A1 | Combination of loop diuretics with adenosine A1-receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-01-12 | — | — | EP | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| EP-0322206-B1 | Compositions and methods for improving cold tolerance in animals and humans | CA MINISTER NAT DEFENCE (CA) | 1995-05-24 | — | — | EP | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| US-5192740-A | Adenosine receptor antagonist | UNIVERSITY OF ALBERTA (CA) | 1993-03-09 | — | — | US | claimed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | claimed |
| US-4593095-A | ADENOSINE RECEPTOR ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1986-06-03 | — | — | US | claimed |
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3876871-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | The Regents of the University of California (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-1904020-A2 | NEW SLIMMING COSMETIC COMPOSITIONS | Sederma S.A.S. (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007010478-A2 | SLIMMING COSMETIC COMPOSITIONS | SEDERMA (FR) | 2007-01-25 | — | — | WO | disclosed |
| EP-0322206-A2 | Compositions and methods for improving cold tolerance in animals and humans | HER MAJESTY IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 1989-06-28 | — | — | EP | disclosed |
| US-4783530-A | CARDIOTONIC AND BRONCHODILATOR AGENTS | MARION LABORATORIES, INC. (US) | 1988-11-08 | — | — | US | disclosed |
| US-4769377-A | Adenosine receptor antagonists | THE JOHNS HOPKINS UNIVERSITY (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0267607-A1 | 8-Arylxanthines | MARION MERRELL DOW INC. (US) | 1988-05-18 | — | — | EP | disclosed |
| US-4593095-A | ADENOSINE RECEPTOR ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | PER2, NCOR2, NR4A2 | ADORA2B 672/4885ADORA2A 254/4885ADORA1 577/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | ADORA2B 826/4885ADORA2A 414/4885ADORA1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.